PharmaCord, a pharma services company, secures investment from Permira. The deal’s value was not made public. It is anticipated to close by the fourth quarter of 2024 and is subject to standard regulatory approvals.
The money will be used by the company to grow both its operations and its clientele. Along with the Permira funds, PharmaCord’s founder and CEO, Nitin Sahney, and the management group will continue to hold key positions and drive the organisation.
With the aim of improving the patient experience, it is a pharmaceutical services firm that works with life sciences organisations to commercialise their products. Its all-inclusive solutions enhance the specialty pharmaceutical patient journey by offering a variety of services that increase awareness, ease treatment access, lower costs, and encourage therapy adherence.
Read also – [Funding News] TX-based Vantage Discovery Secures $16Million in Series A Round Funding
Through its different programmes, the firm promotes over 100 pharmaceutical items and maintains ties with over 30 pharmaceutical clients. It makes it easier for patients to obtain and take their essential prescriptions by utilising a non-commercial pharmacy called PharmaCord ScriptsTM, team members, and a suite of patented technologies.
About PharmaCord
PharmaCord is a patient services company, trusted by top manufacturers to improve medication access, adherence, and patient satisfaction. With their help, patients have a better experience with their critical therapies.
